Novel Paired Cell Lines for the Study of Lipid Metabolism and Cancer Stemness of Hepatocellular Carcinoma

Yun-Hsin Cheng, Ying-Chieh Ko, Hsiang‐Ju Ku, Ching-Chun Huang, Yu-Ching Yao, Yi-Tzu Liao, Ying-Tsong Chen, Shiu‐Feng Huang, Li–Rung HuangFrontiers in Cell and Developmental Biology 2022 · DOI

TL;DR

Researchers have developed two novel, well-characterized mouse cell lines (NHRI-1-E4 and NHRI-8-B4) that mimic key aspects of human hepatocellular carcinoma (HCC). These cell lines, derived from a unique transposon-induced mouse model, exhibit distinct lipid metabolism profiles and cancer stemness characteristics, offering a valuable tool for studying HCC progression and developing new therapies.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) is a major global health concern. Developing effective immunotherapies and treatments for HCC is hampered by a lack of suitable experimental models. Specifically, there's a need for well-characterized, syngeneic (genetically identical) mouse models that can accurately reflect the complexity of HCC, including its diverse cellular phenotypes and interactions with the immune system. Existing models often fall short in these areas, limiting our ability to study cancer stemness and test new therapeutic strategies. This paper addresses this gap by creating and characterizing two new HCC cell lines that offer distinct advantages for such research.

Methods

The study utilized a sophisticated approach to generate and analyze these novel cell lines:

  • Transposon-mediated oncogene insertion: The researchers employed the Sleeping Beauty (SB) transposon system to stably integrate oncogenes (AKT and NRASV12) into the genome of mouse hepatocytes. This method allows for targeted gene delivery and the creation of a spontaneous HCC model.
  • Tumor clone isolation and characterization: Following tumor development, individual tumor clones were isolated. These clones were then subjected to extensive characterization, including:
  • Flow cytometry: To identify and sort specific cell populations (e.g., CD45- PDGFRα- CD44+).
  • Western blotting: To assess protein expression levels of key signaling molecules like AKT and NRAS.
  • Luciferase activity assays: To quantify tumor growth and viability.
  • BODIPY staining and FACS analysis: To measure intracellular lipid droplet (LD) content.
  • Sphere formation assays: To evaluate cancer stem cell-like properties.
  • Nanopore Whole Genome Shotgun Sequencing: To precisely map the integration sites of the introduced oncogenes (AKT and NRASV12) within the host genome. This is a crucial step to ensure the observed differences between clones are not due to random integration events.
  • RNA-Seq analysis: To comprehensively analyze gene expression profiles, focusing on pathways related to lipid metabolism, glycolysis, and cancer stemness.
  • Quantitative PCR (qPCR): To validate RNA-Seq findings for specific genes.
  • Immunohistochemistry (IHC): To examine protein expression in tumor tissues.
  • In vivo studies: Subcutaneous and intrasplenic injections of cell lines into mice to assess tumor growth, aggressiveness, and immune cell infiltration.

Datasets

The study did not introduce new benchmark datasets for training or evaluation. Instead, it generated novel cell line data from their established mouse model. The gene expression data from RNA-Seq was analyzed using standard bioinformatics tools and publicly available databases for gene set enrichment analysis (GSEA). The integration site data was mapped against the Mus musculus genome assembly (GRCm39 reference Annotation Release 109).

Key Insights and Ideas

  • Distinct lipid profiles drive different phenotypes: The most striking finding is how variations in lipid droplet (LD) content between the two cell lines (NHRI-8-B4 with high LDs, NHRI-1-E4 with low LDs) correlate with significant differences in their in vivo behavior and interaction with the immune system. This highlights the critical role of lipid metabolism in HCC progression.
  • Cancer stemness is linked to lipid metabolism: The study strongly suggests that both endogenous fatty acid synthesis and exogenous monounsaturated fatty acid (MUFA) consumption promote cancer stemness. This provides a direct mechanistic link between metabolic processes and the aggressive, treatment-resistant characteristics of cancer stem cells.
  • Syngeneic models are crucial for immunotherapy research: The development of these paired cell lines, which express MHC class I and exhibit stable tumor growth, makes them more suitable for immunological studies compared to existing models like Hepa1-6. This is vital for advancing HCC immunotherapy research.
  • IL-4/IL-13 signaling as a driver of proliferation: The high-lipid clone (NHRI-8-B4) shows increased expression of the type II IL-4 receptor, which appears to promote tumor proliferation by interacting with IL-4 or IL-13. This identifies a novel signaling pathway potentially exploitable for therapeutic intervention.
  • Identical integration sites, divergent phenotypes: Despite having identical integration sites for the introduced oncogenes, the two cell lines exhibit distinct features. This suggests that intratumoral differentiation and in vitro selection play significant roles in shaping the diverse cellular phenotypes within a tumor, even when initiated by the same genetic alterations.

Key Results

  • Two novel HCC cell lines (NHRI-1-E4 and NHRI-8-B4) were established and characterized. These lines are derived from an AKT/NRAS-driven spontaneous HCC mouse model.
  • NHRI-8-B4 cells exhibit higher lipid content and stronger cancer stemness compared to NHRI-1-E4 cells and the Hepa1-6 cell line.
  • NHRI-8-B4 cells are more aggressive in vivo, showing faster tumor growth and higher incidence in orthotopic models.
  • Lipid metabolism pathways are differentially regulated: NHRI-8-B4 cells show enrichment in genes related to fatty acid uptake, synthesis, and glycolysis.
  • Cancer stemness markers (CD44, CD133) are upregulated in both novel cell lines compared to Hepa1-6.
  • NHRI-8-B4 cells recruit more immune cells (neutrophils, monocytes, macrophages) to the tumor microenvironment (TME) compared to NHRI-1-E4 cells, partly due to higher chemokine expression (Cxcl2, Cxcl3).
  • NHRI-8-B4 cells are more resistant to sorafenib than NHRI-1-E4 cells and Hepa1-6 cells.
  • The integration sites of AKT and NRAS oncogenes were precisely mapped to identical locations in both cell lines, confirming their shared origin.

Limitations and Future Work

  • Limited in vitro growth difference: While NHRI-8-B4 cells show stronger in vivo growth and stemness, their in vitro proliferation rates were similar to NHRI-1-E4 cells. This suggests that in vivo factors or the tumor microenvironment play a crucial role in their aggressive behavior.
  • Further investigation of cytokine receptor roles: The study identified upregulated cytokine receptors in NHRI-8-B4 cells, particularly the IL-4 receptor. Further research is needed to fully elucidate the mechanisms by which these receptors contribute to tumor progression and immune modulation.
  • Elucidating the role of FABPs: The increased expression of FABP4 and FABP5 in NHRI-8-B4 cells warrants further investigation into their specific roles in regulating lipid metabolism and gene expression in HCC.
  • Therapeutic targeting: The distinct metabolic and stemness profiles of these cell lines present opportunities for developing targeted therapies. The authors suggest exploring agents that target aberrant lipid metabolism, cancer stemness pathways, or specific cytokine receptors.
  • Immune interplay: While the study highlights differences in immune cell recruitment, further detailed analysis of the immune microenvironment and its impact on tumor progression and therapeutic response is needed.

Summary updated

Abstract

There are few well-characterized syngeneic murine models for hepatocellular carcinoma (HCC), which limits immunological studies and the development of immunotherapies for HCC. We previously established an oncogene-induced spontaneous HCC mouse model based on transposon-mediated oncogene (<i>AKT</i> and <i>NRASV12</i>) insertion into the genome of hepatocytes to induce tumorigenesis. Two tumor clones with different levels of lipid droplets (LDs) showed similar <i>in vitro</i> growth but distinctive <i>in vivo</i> phenotypes, including divergent proliferative capability and varying induction of myeloid-derived suppressor cells (MDSCs). The two clones showed distinct gene expression related to lipid metabolism, glycolysis, and cancer stemness. Endogenous fatty acid (FA) synthesis and exogenous monounsaturated fatty acid (MUFA) consumption promoted both tumor proliferation and cancer stemness, and upregulated c-Myc in the HCC cell lines. Moreover, the LD<sup>hi</sup> HCC cell line expressed a higher level of type II IL-4 receptor, which promoted tumor proliferation through binding IL-4 or IL-13. The chromosomal DNA of two tumor clones, NHRI-8-B4 (LD<sup>hi</sup>) and NHRI-1-E4 (LD<sup>lo</sup>) showed five identical <i>AKT</i> insertion sites in chromosomes 9, 10, 13, 16 and 18 and two <i>NRAS</i> integration sites in chromosomes 2 and 3. Herein, we describe two novel HCC cell lines with distinct features of lipid metabolism related to cancer stemness and differential interplay with the immune system, and present this syngeneic HCC mouse model as a practical tool for the study of cancer stemness and discovery of new therapies targeting liver cancers.
BibTeX
@inproceedings{cheng2022novel,
  author = {Yun-Hsin Cheng and Ying-Chieh Ko and Hsiang‐Ju Ku and Ching-Chun Huang and Yu-Ching Yao and Yi-Tzu Liao and Ying-Tsong Chen and Shiu‐Feng Huang and Li–Rung Huang},
  title = {{Novel Paired Cell Lines for the Study of Lipid Metabolism and Cancer Stemness of Hepatocellular Carcinoma}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2022},
  doi = {10.3389/fcell.2022.821224},
}
Figure